What is Kerendia (finerenone) and how is it used in adults with chronic kidney disease associated with type 2 diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Kerendia (Finerenone)?

Kerendia (finerenone) is a first-in-class, nonsteroidal mineralocorticoid receptor antagonist (MRA) approved to reduce the risk of kidney disease progression and cardiovascular events in adults with chronic kidney disease associated with type 2 diabetes. 1

Medication Class and Mechanism

Kerendia is a selective, nonsteroidal MRA that differs fundamentally from older steroidal MRAs (spironolactone, eplerenone) in both its pharmacology and clinical profile 2, 3. It works by blocking pathological overactivation of mineralocorticoid receptors driven by aldosterone, which is a key driver of inflammation and CKD progression in diabetic kidney disease 3.

FDA-Approved Indications

Kerendia has two distinct FDA-approved indications 1:

  1. CKD associated with type 2 diabetes: To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure

  2. Heart failure with preserved or mildly reduced ejection fraction (LVEF ≥40%): To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits

Clinical Evidence and Benefits

Kidney and Cardiovascular Protection in Diabetic CKD

The FIDELITY pooled analysis (combining FIDELIO-DKD and FIGARO-DKD trials with 13,171 patients) demonstrated that finerenone provides 4:

  • 14% reduction in composite cardiovascular outcomes (cardiovascular death, MI, stroke, heart failure hospitalization): HR 0.86,95% CI 0.78-0.95
  • 23% reduction in composite kidney outcomes (sustained ≥57% eGFR decrease or kidney failure): HR 0.77,95% CI 0.67-0.88
  • 36% reduction in end-stage kidney disease specifically: HR 0.64,95% CI 0.41-0.995
  • 29% reduction in heart failure hospitalizations: HR 0.71,95% CI 0.56-0.90

These benefits occurred across the full spectrum of CKD severity in patients with type 2 diabetes and albuminuria 5.

Dosing and Administration

Starting Dose Based on eGFR 1:

  • eGFR ≥60 mL/min/1.73 m²: Start 20 mg once daily
  • eGFR 25-59 mL/min/1.73 m²: Start 10 mg once daily
  • eGFR <25 mL/min/1.73 m²: Initiation not recommended

Critical Pre-Treatment Requirements 1:

  • Serum potassium must be ≤5.0 mEq/L before starting (FDA label)
  • Measure both potassium and eGFR at baseline

Monitoring Protocol 6, 7:

Check potassium at 1 month after initiation, then every 4 months:

  • K+ ≤4.8 mEq/L: Increase dose from 10 mg to 20 mg daily (if eGFR stable)
  • K+ 4.9-5.5 mEq/L: Continue current dose, monitor every 4 months
  • K+ >5.5 mEq/L: Hold finerenone, address hyperkalemia with dietary/medication adjustments, restart at 10 mg when K+ ≤5.0 mEq/L

Place in Therapy According to Guidelines

KDIGO 2024 Recommendations 6:

Finerenone is suggested for adults with type 2 diabetes, eGFR >25 mL/min/1.73 m², normal potassium, and albuminuria (>30 mg/g) despite maximum tolerated RAS inhibitor dose (Grade 2A).

The guidelines emphasize that nonsteroidal MRAs are most appropriate for patients at high risk of CKD progression and cardiovascular events demonstrated by persistent albuminuria despite standard-of-care therapies 6.

Layered Treatment Approach 6, 7:

Finerenone can be added to both RAS inhibitors and SGLT2 inhibitors for comprehensive cardiorenal protection. The 2025 ADA Standards note that finerenone, SGLT2 inhibitors, and GLP-1 RAs can be used interchangeably or together, with clinicians using best judgment for sequencing 4.

Safety Profile

Hyperkalemia Risk

The most significant adverse effect is hyperkalemia 8, 5:

  • Incidence: 10.8% with finerenone vs. 5.3% with placebo
  • Discontinuation rate: Only 1.2% stopped due to hyperkalemia in clinical trials
  • No deaths related to hyperkalemia occurred in the pivotal trials 8

This represents a substantially lower hyperkalemia risk compared to steroidal MRAs like spironolactone, which showed 26.4% hyperkalemia incidence vs. 17.2% with finerenone in comparative real-world data 9.

Comparative Safety

Real-world evidence suggests finerenone is associated with 9:

  • Lower all-cause mortality: aHR 0.31 vs. spironolactone
  • Lower major adverse cardiovascular events: aHR 0.74
  • Lower major adverse kidney events: aHR 0.47
  • Significantly less hyperkalemia than spironolactone

Key Clinical Pearls

Patient Selection: Prioritize finerenone for patients with type 2 diabetes and CKD who have persistent albuminuria despite RAS inhibitor therapy, particularly those at high cardiovascular risk 6.

Combination Therapy: Finerenone provides additive benefits when combined with SGLT2 inhibitors—only 4.5% of FIDELIO-DKD participants were on SGLT2 inhibitors, suggesting most benefit data comes from patients not yet on these agents 8, 5.

Potassium Management: The key to successful finerenone use is proactive potassium monitoring and dose adjustment rather than automatic discontinuation. Most hyperkalemia can be managed with dietary counseling and medication adjustments 6, 7.

Contraindications: Exclude patients with heart failure with reduced ejection fraction and uncontrolled hypertension, as these were exclusion criteria in the cardiovascular outcome trials 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.